New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients.

Anavex-1-1666x833.png

International Conference on Clinical Trials for Alzheimer’s Disease (CTAD) 2015, Barcelona, Spain

Steve Macfarlane, Paul Maruff, Marco Cecchi, Dennis Moore, Tasos Zografidis, Christopher Missling


View Presentation

1/0